SBIR/STTR Research Award

EVALUATION OF RETROVENOUS MYOCARDIAL DRUG DELIVERY SYSTEM

Award identifier 782986d262e13796aeb526602bac09c93c1717b8ecc90b9cf5b7bead03baeb2eAwarding agency Department of Health and Human Services

Award amount

$484,000

Program and phase

SBIR · Phase II

Award year

1988

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
Not reported
Recipient company
Utah Biomedical Test Labs
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

THE FEASIBILITY OF RETROVENOUS MYOCARDIAL DRUG DELIVERY (XYLOCAINE) TO TREAT AND CONTROL ARRHYTHMIAS WILL BE TESTED IN SHEEP AFTER CORONARY ARTERY OCCULSION, AND THEN COMPARED TO THE STANDARD INTRAVENOUS ROUTE. ENDPOINTS OF NUMBER AND TYPE OF ARRHYTHMIAS, XYLOCAINE DOSE, PLASMA, AND MYOCARDIAL XYLOCAINE CONCENTRATIONS WILL BE DETERMINED. THE DEMONSTRA-TION OF THE HYPOTHESIS THAT RETROVENOUS MYOCARDIAL DRUG DELIVERY IS SUPERIOR TO INTRAVENOUS THERAPY AFTER CORONARY ARTERY OCCLUSION COULD PROVIDE AN EFFECTIVE METHOD FOR THE TREATMENT OF VENTRICULAR ARRHYTHMIAS.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.